Drugs / Lifibrol
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01057654 | Jan → Apr 1996 | hyperlipidemia, hyperlipoproteinemia | University Hospital, Bonn | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lifibrol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01057654 ↗ |
| Known as | 4-(4'-tert. butylphenyl)-1-(4'-carboxyphenoxy)-2-butanol | “Lifibrol (K12.148; 4-(4'-tert. butylphenyl)-1-(4'-carboxyphenoxy)-2-butanol) given as a 600 mg film-coated tablet” NCT01057654 ↗ |
| Known as | K12.148 | “Lifibrol (K12.148; 4-(4'-tert. butylphenyl)-1-(4'-carboxyphenoxy)-2-butanol) given as a 600 mg film-coated tablet” NCT01057654 ↗ |
| Modality | Small molecule | — CHEMBL2105019 ↗ |
| Target | LDLR | “it increases hepatic LDL receptor expression” NCT01057654 ↗ |